 REVIEW ARTICLE

Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives

Yoshihiko Maehara · Shunichi Tsujitani · Hiroshi Saeki · Eiji Oki · Keiji Yoshinaga · Yasunori Emi · Masaru Morita · Shunji Kohnoe · Yoshihiro Kakeji · Tokujiro Yano · Hideo Baba

Received: 24 August 2011 / Accepted: 7 September 2011 / Published online: 6 December 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.

Keywords PSK · Biological mechanism · Gastric cancer · Colorectal cancer · Biomarker

Introduction

Whether human immunity is effective against cancer, which originates from mutation of the host’s normal cells, has long been a subject of skepticism. In 1991, van der Bruggen et al. [1] identified the tumor antigen in human melanoma that is recognized by cytotoxic T lymphocytes (CTLs) and proved at the molecular level that host immunity acts also against cancer. Thereafter, immunotherapy was developed mainly along the lines of vaccine therapy and cell therapy, with the aim of boosting specific immunity [2]. Research began to show that antigen-nonspecific innate immunity and antigen-specific acquired immunity are closely associated via the dendritic cells (DCs) that possess the important function of antigen presentation [3]. Also, antigen-presenting cells (APCs), including DCs, are known to be activated by recognizing various foreign pathogens via the Toll-like receptors (TLRs) [4]. These developments indicate that activation of nonspecific immunity plays certain roles in augmenting antitumor immunity. However, the antitumor effect of biological response modifiers (BRMs) is not necessarily potent [5]. For this reason, they have been used in combination with chemotherapy. The effect of chemotherapy is known to be affected by the performance status (PS) and nutritional and immune status of the patient [6–8]. Recently, Apetoh et al. [9] have presented basic research evidence that tumor cells damaged by chemotherapy release high mobility group box 1, which interacts with TLR4 to
stimulate DCs and activates antitumor immunity, and these activities contribute to the success of chemotherapy. Clinically, these investigators also have reported earlier relapse after combined anthracycline-based chemotherapy and local radiotherapy in breast cancer patients with a functionally deficient TLR4 polymorphism, compared to breast cancer patients with normal TLR4. These findings show the importance of the host’s immune capacity during chemotherapy, and suggest the importance of nonspecific immune activation in cancer patients whose immune functions are compromised.

Protein-bound polysaccharide K (PSK; KRESTIN®) is isolated and purified from the cultured mycelium of the Basidiomycete *Coriolus versicolor*, has an average molecular weight of approximately 100,000, and contains 18–38% protein. PSK exhibits antitumor activity against various experimental tumors, and nonspecific immunomodulatory activity is considered the principal mechanism of action of this agent [10]. PSK has been shown to regress tumors clinically, and was approved in 1976 for the treatment of cancers of the digestive organ, lung and breast. Clinical use in Japan was started in 1977. After reevaluation in 1989, PSK was approved for use in combination with chemotherapy to prolong survival of patients with gastric cancer (resected cases) or colorectal cancer (curatively resected cases), and to prolong remission of patients with small-cell lung carcinoma.

Along with advances in molecular biology and tumor immunology, many investigators have conducted research on the mechanisms of action of PSK and have built up substantial knowledge. Studies on clinical effects are still ongoing, mainly in accordance with the currently approved indications. The present article reviews the recent developments in research on the biological mechanisms of PSK and the major clinical results reported to date, to identify the challenges for the future.

**Biological mechanism of PSK**

Although the importance of BRMs in cancer treatment has been proven, better understanding of their mechanisms of action is essential for optimal application of these compounds. For PSK, three main mechanisms have been revealed (Fig. 1) [11]. First, PSK improves host immunocompetence by inhibiting the production of or neutralizing immunosuppressive substances that are increased in cancer. Second, PSK activates immune cells such as lymphocytes, either directly or by regulating the production of various cytokines. Third, PSK acts directly on cancer cells. These mechanisms are considered to support the clinical effectiveness of PSK in suppressing cancer relapse.

**Suppressed production or neutralization of immunosuppressive factors** (Table 1)

It is well known that various humoral factors induce immunosuppression in cancer-bearing individuals. PSK restores or attenuates this suppression, as demonstrated by a larger number of reports showing abrogation of the immunosuppressive effects of serum obtained from cancer-bearing animals or cancer patients, inhibition of transforming growth factor (TGF-β) production or antagonism against TGF-β, and lowering of serum level of immunosuppressive acidic protein (IAP) and prostaglandin E2 (PGE2) production [12–17]. In addition, PSK has been reported to possess antioxidant activity [18]. No other drug exhibits such diverse actions as a single agent, and this is the characteristic of PSK.

In an in vitro study using peripheral blood mononuclear cells (PBMCs) from healthy volunteers, Yamaguchi et al. [19] have reported that PSK enhances interleukin-2 (IL-2)-induced proliferation of lymphokine-activated killer (LAK) cells and their cytotoxic activity, and abolishes the TGF-β-induced inhibition of LAK activity. They speculated that PSK acted on TGF-β receptors to block the association between TGF-β and its receptors. Thus, PSK seems to inhibit the effects of TGF-β through various mechanisms including suppression of TGF-β production, direct binding with TGF-β, and acting on TGF-β receptors.

IL-10 shows various immunosuppressive activities, and elevated serum levels of IL-10 have been reported as a negative prognostic factor. Shibata et al. [20, 21] have...
studied the effect of PSK on IL-10. They found that IL-10 production was suppressed when PSK was added in vitro to phytohemagglutinin (PHA)-stimulated PBMCs from patients with advanced colorectal cancer, and that IL-10 production by PHA-stimulated PBMCs from advanced colorectal cancer patients was reduced after 2 months of immunochemotherapy with PSK, compared to that before treatment.

Tsujitani et al. [22] have examined the effect of PSK on the expression of natural killer group 2D (NKG2D), a receptor that activates CD8+ T cells and natural killer (NK) cells. When PBMCs from healthy volunteers were co-cultured with the human gastric cancer cell line MKN-45, NKG2D expression on CD8+ T cells was downregulated, while the addition of PSK restored NKG2D expression on CD8+ T cells. The authors suggested that direct contact between CD8+ T cells and gastric cancer cells was necessary for the downregulation of NKG2D expression. These findings raise interest on how PSK affects the interaction between tumor cells and T cells.

The suppressive effect of tumor-derived factors on DCs and the ability of PSK to overcome this effect have been studied. Okuzawa et al. [23] have studied the in vitro differentiation of peripheral blood CD14+ cells into DCs and reported that the addition of the culture supernatant of human gastric cancer cells MKN-45P downregulated the surface markers of DC maturation, decreased IL-12 production, and increased apoptosis of DC. Addition of PSK restored all these changes to the levels observed in the absence of the culture supernatant. These findings suggest that, by reversing the defective DC differentiation and function, PSK is able to augment the subsequent immune response.

It is well known that surgical stress lowers the immune response. PSK has been reported to attenuate the immunosuppression due to surgical invasion [24]. Using a mouse laparotomy model, Ooshiro et al. [25] have found that concanavalin-A-stimulated interferon (IFN)-γ (Th1 cytokine) and IL-4 (Th2 cytokine) production by spleen cells was decreased, and the decrease in IFN-γ was especially marked, which resulted in a low IFN-γ/IL-4 ratio. In mice treated with PSK before laparotomy, the decreases in IFN-γ and IL-4 production were ameliorated, the recovery of IFN-γ production was especially marked, and the IFN-γ/IL-4 ratio was restored. The resultant Th1/Th2 balance shifted to Th1 dominance. The ability of PSK to correct the Th1/Th2 imbalance, to be described later, could also work during the perioperative period.

Many basic studies on the effects of the combined use of PSK with chemotherapy have been reported. While chemotherapy induces leukopenia and depresses immunity, PSK inhibits these adverse effects [26]. The ability of PSK to prevent chemotherapy-depressed immunity is one of the mechanisms that accounts for the benefit of PSK in combined therapy. Kono et al. [27] have examined apoptosis of peripheral blood T cells in gastric cancer patients treated with oral fluoropyrimidine agent tegafur–gimeracil–oteracil potassium (S-1; TS-1®), alone or in combination with PSK. While an increase in T-cell apoptosis concomitant with elevation of caspase-3 and Bax expression was observed in patients treated with S-1 alone, these increases were partially prevented in patients treated with S-1 and PSK (Fig. 2). The mechanism has been speculated as ensuing from the antioxidant activity of PSK, which counteracts the increase in reactive oxygen species resulting from chemotherapy.

Regulation of immune cells and cytokine production (Table 2)

Antitumor immune responses involve complex interactions among various immune cells and cytokines (Fig. 3). PSK exerts various effects on the immune cells, and its effects on lymphocytes, helper T cells, CTLs, NK cells, LAK

| Table 1 Suppressed production or neutralization of immunosuppressive factors |
|-------------------------------|-----------------------------|-----------------------------|
| **Immunosuppressive factors** | **Subjects/animals/cells**  | **Key observations**         | **References** |
|-------------------------------|-----------------------------|-----------------------------|----------------|
| Cytokine                      | PBMCs of healthy volunteers | Abrogation of inhibition of LAK activities by TGF-β | Yamaguchi [19] |
| Cancer cell                   | PBMCs of colorectal cancer patients | Suppression of IL-10 production | Shibata [20, 21] |
| Tumor culture supernatant    | CD14+ cells in peripheral blood of healthy volunteers | Prevention of defective maturation of DCs by tumor culture supernatant | Okuzawa [23] |
| Surgical stress              | Mice                        | Correction of Th1/Th2 imbalance | Ooshiro [25] |
| Chemotherapy                  | Gastric cancer patients     | Partial prevention of S1-induced peripheral blood T-cell apoptosis | Kono [27] |

PBMC peripheral blood mononuclear cell, LAK lymphokine-activated killer, TGF-β transforming growth factor-β, NKG2D natural killer (NK) group 2D, DC dendritic cell, S-1 tegafur–gimeracil–oteracil potassium
cells, and macrophages have been reported in numerous publications [28–36]. In addition, the effects of PSK on the production of various cytokines and nitric oxide (NO) have been reported [37, 38]. García-Lora et al. [39, 40] have used the human NKL cell line to study the intracellular signal transduction pathway involved in the activation of NK cells by PSK. PSK activates protein kinase C (PKC)\(\delta\), PKC\(\epsilon\), and extracellular signal-regulated kinase (ERK)2 and ERK3, and increases DNA binding of activator protein-1 (AP-1) and cAMP response element (CRE) transcriptional factor. Asai et al. [41] have shown that the addition of PSK in the stimulation of mesenteric lymph node CD4\(^+\) T cells with anti-CD3 antibody increased the production of IL-2, IFN-\(\gamma\), and IL-4. They reported that the signaling pathway involved the activation of linker for activation of T cells (LAT), ERK1/2, nuclear factor of activated T cells, and AP-1. Although the actions of PSK on immune cells differ slightly depending on the cell type, these actions have started to unfold at the level of the signal transduction pathway. Further accumulation of data using different immune cells under various conditions might provide a comprehensive picture of the action of PSK.

As mentioned earlier, DCs play an important role in the immune response. In the peripheral blood, DCs exist in an immature state. Upon maturation by the actions of inflammatory cytokines, they activate T cells and induce acquired immunity. Kanazawa et al. [42] have reported that the addition of PSK to cultures of peripheral blood CD14\(^+\) mononuclear cells from healthy adults and advanced cancer patients with IL-4 and granulocyte-macrophage colony stimulating factor for DC differentiation potentiates the expression of maturation surface markers, such as CD83, production of IL-12, and induction of CTLs. Using a similar in vitro system, Ogihara et al. [43] have reported similar results with the addition of PSK.

![Fig. 2 Effect of oral administration of PSK on apoptosis of circulating T cells induced by the anticancer drug S-1 in gastric cancer patients. Adapted and modified from Kono et al. [27]](image-url)

Table 2 Regulation of immune cells and cytokine production

| Immune cells | Subjects/animals/cells | Key observations | References |
|--------------|------------------------|------------------|------------|
| NK cells     | Human NK cell line     | Activation of PKC\(\delta\), PKC\(\epsilon\), ERK2, ERK3, AP-1 and CRE transcriptional factor | García-Lora [39, 40] |
| T cells      | CD4\(^+\) T cells in murine mesenteric lymph node | Activation of LAT, ERK1/2, NFAT and AP-1 | Asai [41] |
| DCs          | CD14\(^+\) mononuclear cells in PBMC of healthy volunteers | Promotion of maturation of DCs | Kanazawa [42], Ogihara [43] |
| Th1/Th2      | PBMC of human healthy volunteers | Increase of TNF-\(\alpha\) production and decrease of IL-10 production by stimulation of human gastric cancer cell lysate | Sugiyama [45] |
|              | Colorectal cancer patients | Decrease of proportion of IL-10\(^+\) CD4\(^+\) T cells (Th2) in peripheral blood | Yoshino [46] |
| B cells      | Human B cell line      | Enhancement of IgM production | Maruyama [49] |
| Monocytes    | Human cord blood mononuclear cells | Activation of T cells and induction of CTLs through increase of IL-15 and LTB\(_4\) production by monocytes in EBV-infected cultures | Liu [50–52], Klein [53] |
| NKT cells    | Gastric cancer patients | Decrease of CD57\(^+\) T cells in peripheral blood | Akagi [54] |
| Others       | Murine peritoneal macrophages, etc. | Inhibition of binding of LPS to LBP, protection of LPS-induced lethality | Asai [55] |
| Mouse model of DSS and DMH-induced inflammatory bowel disease and colorectal carcinogenesis | Antagonistic effects on inflammation and carcinogenesis | Tsutsumi [57] |

NK natural killer, PKC protein kinase C, ERK extracellular signaling regulated kinase, AP-1 activator protein-1, CRE cAMP-response element, LAT linker for activation of T cells, NFAT nuclear factor of activated T cells, DC dendritic cell, PBMC peripheral blood mononuclear cell, TNF-\(\alpha\) tumor necrosis factor-\(\alpha\), CTL cytotoxic T lymphocyte, LTB\(_4\) leukotriene B\(_4\), EBV Epstein–Barr virus, LPS lipopolysaccharide, LBP LPS-binding protein, DSS dextran sodium sulfate, DMH 1,2-dimethylhydrazine
PSK treatment, although the proportion of IFN-γ decreases by flow cytometry before and after treatment. After surgery and examined the peripheral blood Th1/Th2 ratio of PBMCs from healthy adults stimulated with tumor antigen peptides on MHC class I molecules activate naïve CD8+ T cells, whereas the antigen peptides on MHC class II molecules activate naïve CD4+ T cells (T-helper cell precursors). T-helper cell precursors differentiate into Th1 and Th2 cells. Th1 cells produce cytokines, including IL-2 and IFN-γ. These cytokines induce proliferation and activation of tumor antigen-specific CTLs, activation of NK cells and macrophages, and induction of LAK cells. Through the actions of the APCs, T cells are activated and naïve CD4+ T cells differentiate into Th1 or Th2 cells.

In a cancer-bearing state, the Th1/Th2 balance shifts to Th2 dominance; therefore, cellular immunity, which is the main component of antitumor immunity, does not function efficiently [44]. Sugiyama et al. [45] have examined cytokine production of PBMCs from healthy adults stimulated with tumor antigen peptides obtained by freezing and thawing a gastric cancer cell line after 1 week. Addition of PSK did not change IFN-γ production, but increased tumor necrosis factor-α (TNF-α) (Th1 cytokine) production and decreased IL-10 (Th2 cytokine) production. Yoshino et al. [46] treated colorectal cancer patients with PSK for 1 week before surgery and examined the peripheral blood Th1/Th2 balance by flow cytometry before and after treatment. After PSK treatment, although the proportion of IFN-γ-producing CD4+ T cells (Th1) did not change, the proportion of IL-10-producing CD4+ T cells (Th2) decreased. These studies suggested that PSK appeared to act mainly to suppress Th2, and PSK shifted the Th1/Th2 balance to Th1 dominance to augment antitumor immunity.

Various monoclonal antibodies have been developed for cancer treatment. PSK has been reported to augment antibody-dependent cell cytotoxicity [47]. The effect of PSK on antibody production is considered to act via helper T cells [48]. Maruyama et al. [49] have reported that PSK directly enhances the proliferation and IgM production of the human B cell line BALL-1, which suggests that PSK also acts directly on the humoral immunity pathway to potentiate acquired immunity.

Most of the studies on the effects of PSK on immune cells or cytokine production have been conducted by targeting individual immune cells or cytokines. In vivo, however, the immune response is a cascade reaction that involves many immune cells and cytokines. Liu et al. [50–52] have investigated the effect of PSK on the immune response against Epstein–Barr virus (EBV) infection, using human cord blood mononuclear cells (CBMCs) that contain various types of immune cells. The addition of PSK to EBV-infected CBMCs increases expression of signaling lymphocytic-activation molecule-associated protein (SAP), which is an indicator of T- and NK cell activation. PSK also induces EBV-specific CD4+ CTLs, and inhibits proliferation of the potentially malignant EBV-infected B cells. Liu et al. have further demonstrated that the presence of monocytes and monocyte-derived IL-15 and leukotriene B4 (LTB4) is necessary for the upregulation of SAP expression by PSK. Klein et al. [53], have reported that the interaction between T cells activated by EBV-infected B cells and monocytes activated by PSK occurs via CD40 ligand and CD40, and that these cells together with NK cells activated by EBV-infected B cells progress to a functionally activated state, which produces IL-15, IFN-γ, and LTB4 to induce CD4+ CTLs. IL-15 has been attracting the most attention as an antitumor agent with potential for clinical application (NCI Immunotherapy Agent Workshop, 2007), and studies have demonstrated that PSK induces IL-15.

Akagi et al. [54] have examined the effect of postoperative immunochemotherapy with PSK on immune cells in peripheral blood of gastric cancer patients at 3 months after surgery, and have reported that administration of PSK decreases the proportion of CD57+ T cells that mediate suppressor T-cell functions.

On a slightly different note, Asai et al. [55] have examined the NF-κB activity (indicated by luciferase activity) when the pro-B cell line Ba/F3 transfected with TLR-4 and MD-2 was stimulated with LPS. They have reported that addition of PSK inhibited nuclear factor (NF)-κB activity, which was caused by inhibition of binding between LPS and LPS-binding protein (LBP) by PSK. Administration of PSK also protected mice from LPS-induced lethality, which indicates that PSK is useful for controlling sepsis, which is also interesting from a clinical viewpoint.

Association between chronic inflammation and cancer development has been well described, and various factors released from inflammatory cells have been reported to exacerbate cancer [56]. Using a dextran sodium sulfate (DSS) and 1,2-dimethylhydrazine-induced mouse model of inflammatory bowel disease and colorectal carcinogenesis,
Tsutsumi et al. [57] have shown that PSK administration reduced DSS-induced colitis-related mortality and inhibited colorectal carcinogenesis, which indicates that PSK possesses dual antagonistic effects against inflammation and carcinogenesis. This study offers a new perspective on the mechanism of the action of PSK.

Direct action on tumor cells (Table 3)

It has been demonstrated that PSK directly inhibits the proliferation of cancer cells and induces apoptosis [24, 58, 59]. Also, PSK has been reported to upregulate the expression of human leukocyte antigen (HLA) on human gastric cancer cells [60]. Hattori et al. [61] have examined the effects of PSK on 33 hematological malignant cell lines and have reported that PSK strongly inhibits the proliferation of Namalwa (Burkitt lymphoma) cells and increases apoptosis. It has been shown that inhibition of cell proliferation by PSK is antagonized by the addition of galactose. When Namalwa cells are treated with galactosidase, the effect of PSK is enhanced, which suggests that the galactose-containing structure of the Namalwa cell surface plays an important role in the action of PSK. Jiménez-Medina et al. [62] also have examined the effects of PSK on seven human and mouse cancer cell lines. The inhibitory effect of PSK on cell proliferation differs depending on the cell line. For the AGS (human gastric cancer cell line) cells in which a strong inhibitory effect is observed, arrest of the cell cycle at G1, and increased apoptosis and caspase-3 expression have been observed. From the above results, it is apparent that PSK induces apoptosis of cancer cells, but the effect seems to differ depending on the type of cancer. Further studies should examine the properties of cells in which apoptosis is induced by PSK.

PSK is well known to exhibit anti-metastatic activity in various experimental metastasis models, and the mechanism of action has been reported for each step of metastasis [63]. Two new and interesting reports on the mechanism of the anti-metastatic action of PSK, from the viewpoint of TGF-β suppression, have been published. Zhang et al. [64] have reported that PSK decreases the invasiveness of the human pancreatic cancer cell line, NOR-P1, and the gastric cancer cell line, MK-1P3, by multiple mechanisms that include direct suppression of matrix metalloproteinase (MMP) production, inhibition of the activation of latent TGF-β, and indirect suppression of MMP production through inhibition of TGF-β production. In recent years, the association of epithelial–mesenchymal transition (EMT) with invasion and metastasis of cancer cells has been speculated, and TGF-β has been shown to play an important role in the EMT process [65]. Hayashida et al. [66] have treated SW837 cells (human colorectal cancer cell line with normal TGF-β receptor and signal transduction) with TGF-β followed by PSK, and have found that nuclear translocation of the TGF-β signal transducer Smad2 was inhibited, and that the expression of genes including the TGF-β target gene SERPINE-1 was also inhibited. In addition, they performed

**Table 3** Direct actions on tumor cells

| Targets of PSK action | Animals/cells | Key observations | References |
|-----------------------|---------------|------------------|------------|
| Apoptosis             | Burkitt lymphoma | Induction of apoptosis | Hattori [61] |
|                       | Human gastric cancer cell line | Induction of G1 arrest and apoptosis | Jiménez-Medina [62] |
| Metastasis            | Human pancreas or gastric cancer cell line | Direct or indirect inhibition of MMP production through TGF-β production and suppression of latent TGF-β activation | Zhang [64] |
|                       | Human colon cancer cell line | Suppression of nuclear localization of Smad2; decreased expression of TGF-β-targeted gene; inhibition of TGF-β-induced EMT | Hayashida [66] |
| Neoangiogenesis       | HUVEC, rat | Inhibition of bFGF-induced cell proliferation through direct binding to bFGF | Wada [68] |
| Gene expression       | Human colorectal cancer cell line | Upregulation of expression of MRP3, lymphotactin, transgelin and pirin | Yoshikawa [70] |
| Combination with chemotherapy | Human pancreas cancer cell line | Inhibition of docetaxel-induced NF-κB activation and cIAP-1 expression, and enhancement of apoptosis induced by docetaxel | Zhang [71] |
|                       | Human gastric cancer cell line | Inhibition of docetaxel-induced NF-κB activation and survivin expression | Kinoshita [72] |

**MMP** matrix metalloproteinase, **TGF-β** transforming growth factor-β, **EMT** epithelial–mesenchymal transition, **HUVEC** human umbilical vein endothelial cells, **bFGF** basic fibroblast growth factor, **MRP3** multidrug resistance protein 3, **NFκB** nuclear factor-κB, **cIAP-1** cellular inhibitor of apoptosis protein.
PSK is known to inhibit angiogenesis [67] and new results on the mechanism have been reported. Wada et al. [68] have shown that PSK administration inhibits basic fibroblast growth factor (bFGF)-induced angiogenesis in rats, and from studies on human umbilical vein endothelial cells, they have speculated that the mechanism is due to direct binding of PSK with bFGF, which results in suppression of bFGF-induced proliferation of endothelial cells. The effect of PSK on vascular endothelial growth factor-induced angiogenesis [69] should also be examined.

Comprehensive gene expression analysis of PSK-treated cancer cells has been attempted. Yoshikawa et al. [70] have used cDNA microarrays to analyze the in vitro effect of PSK on the gene expression profile of the human colorectal adenocarcinoma cell line HCT116, the proliferation of which is inhibited by PSK. After PSK treatment, approximately 450 genes showed altered expression. The expression of genes that were significantly altered was examined further in two cell lines, HCT116 and SW480, using RT-PCR. Multidrug resistance protein 3, lymphotactin, transgelin, and pirin were upregulated in both cell lines. Studies on the relationship between PSK-induced altered gene expression and the biological response are anticipated.

Even when used in conjunction with chemotherapy, PSK directly acts on cancer cells to enhance the effect of combined therapy. Zhang et al. [71] have studied the effect of PSK and low-dose docetaxel on proliferation of the human pancreatic cancer cell line NOR-P1, and have reported the mechanisms as follows. Docetaxel induces apoptosis, but at the same time it also activates NF-κB and induces cellular inhibitor of apoptosis protein (cIAP)-1 expression, to suppress the induction of apoptosis. PSK inhibits the docetaxel-induced NF-κB activation to enhance induction of apoptosis. Kinoshita et al. [72] also have reported that PSK inhibits docetaxel-induced NF-κB activation and survivin expression in the human gastric cancer cell line TMK-1, and enhances antitumor effect of docetaxel through inhibition of survivin expression in tumor tissue in a xenograft model.

**Clinical effect of PSK**

Clinical trials of PSK were started from around 1972, and the early trials demonstrated the effectiveness of PSK as monotherapy or in combination with chemotherapy, which led to the approval of PSK for clinical use in Japan. In 1980, the criteria for the evaluation of immunotherapy for malignant tumors were published. According to these criteria, immunotherapy should be used in combination with other therapies such as chemotherapy, and the evaluation of its effect should include statistically estimating the overall survival (OS) or disease-free survival (DFS), based on randomized control trials (RCTs) using the base therapy as a control [73]. These criteria apply also to PSK. RCTs were planned and conducted, and submitted for reevaluation, which resulted in reapproval for current indications. In addition, the efficacy of PSK has been verified in multiple meta-analyses.

**Gastric cancer (Tables 4, 6)**

Anticancer chemotherapy can be classified into two types: systemic chemotherapy for unresectable metastatic or recurrent cancer, and adjuvant chemotherapy for suppressing postoperative relapse. Almost all the clinical results of PSK belong to the latter type. As a study of the former type, Nakao et al. [74] have conducted a clinical trial to determine the efficacy of PSK in 54 patients with unresectable or postoperative recurrent gastric cancer. Patients were treated with intravenous mitomycin C (MMC) and 5-fluorouracil (5-FU) twice weekly for 2 weeks, followed by intravenous MMC/5-FU once weekly plus oral PSK 3 g/day on consecutive days (chemotherapy + PSK group), or MMC/5-FU alone (chemotherapy group). They reported that, although the response rates were not significantly different between the two groups, the survival rate was significantly improved in the chemotherapy + PSK group. Although unresectable, metastatic, and recurrent gastric cancers are not included in the approved indications for PSK at present, this study does suggest a direction for the potential use of PSK.

The results of postoperative adjuvant chemotherapy for gastric cancer have been reviewed by Maehara et al. [75]. In Japan, many controlled trials of postoperative adjuvant chemotherapy compared with surgery alone were conducted from the 1960s, but few studies have reported significant results in favor of postoperative adjuvant chemotherapy. Kondo et al. [76] have conducted a double-blind trial on 144 stage III surgical patients randomized to receive oral PSK 1–3 g/day from 10–15 days after surgery until relapse or distant metastasis (PSK group), or placebo (control group). They reported that PSK treatment significantly prolonged DFS. Their results indicate that PSK, even when used alone, is effective in some patients, although PSK monotherapy is not an approved usage at present. In the study of Maehara et al. [77], 225 patients who underwent histologically curative resection of advanced gastric cancer were treated postoperatively with intravenous MMC once every 3 months for 1 year, together with oral tegafur and PSK from 7 to 10 days after surgery, for long-term (postoperative long-term cancer chemotherapy group; PLCC), or surgery alone. The long-term (15-year) survival rate was 56.9% in the PLCC group.
and 45.7% in the surgery group, which showed a significant ($P = 0.0351$) survival benefit in the PLCC group (Fig. 4).

Since a subset analysis of multiple clinical trials has shown the effectiveness of postoperative adjuvant chemotherapy compared with surgery alone, studies from the 1980s have compared efficacy between different adjuvant chemotherapies. The effectiveness of PSK as an adjuvant therapy for gastric cancer has been evaluated mainly during this period, by comparing chemotherapy + PSK with chemotherapy alone. To examine the effectiveness of immunostimulators, the Co-operative Study Group of Surgical Adjuvant Chemotherapy for Gastric Cancer (SACG) divided Japan into six blocks in 1978, and each block conducted multicenter RCTs independently in patients with resected gastric cancer, excluding the patients with mucosal cancer having no lymph node metastasis, and compared immunochemotherapy with chemotherapy [78]. In the Chugoku/Kyushu block, 579 patients who underwent curative surgery were given intravenous MMC on the day of and 1 day after surgery, followed 2 weeks later by oral PSK 3 g/day plus tegafur (chemotherapy + PSK group), or PSK alone (PSK group) or tegafur alone (chemotherapy group) for 1 year. Niimoto et al. [79] have reported that the 5-year OS rate in the three groups was 71.7, 64.1, and 58.5%, respectively, and a significant difference ($P < 0.05$) was detected in a three-group comparison. In two-group comparisons, the survival rate was significantly ($P < 0.01$) higher in the chemotherapy + PSK group than in the

### Table 4 RCTs of postoperative adjuvant chemotherapy with PSK for resected gastric cancer

| References or trial | Stage | No. of patients | Treatment | Percent survival/years | $P$ value | Suggestive data (percent survival/years) |
|---------------------|-------|----------------|-----------|------------------------|-----------|----------------------------------------|
| Kondo [76]          | III   | 72             | A: PSK    | Improvement of DFS     | Significant |
|                     |       | 72             | B: Placebo|                        |           |                                        |
| Machara [77]        | Advanced stage | 137          | A: MMC + FT + PSK | 56.9/15           | 0.0351    |                                        |
|                     |       | 118            | B: Surgery alone | 45.7/15           |           |                                        |
| Niimoto [79]        |       | 191            | A: MMC+FT+PSK | 71.7/5               | 3 groups  |                                        |
| SACG                |       | 189            | B: MMC+PSK  | 64.1/5                | <0.05     |                                        |
| Chugoku/Kyushu      |       | 199            | C: MMC+FT   | 58.5/5               | A versus C|                                        |
|                     |       |                |            | <0.01                 |           |                                        |
| Kondo [80]          |       | 145            | A: FT+PSK   | 64.1/8                | 0.410     | A: 86 cases\(^b\), 56.8/8              |
| SACG                |       | 159            | B: FT       | 61.0/8                |           | B: 90 cases\(^b\), 43.6/8              |
|                     |       |                |            |                       |           | $P = 0.071$                            |
| Kondo [82]          | Advanced stage | 47            | A: CQ+PSK   | Not described         | 0.827     | A: 30 cases\(^c\), 43.4/7              |
| TGOG                |       | 49             | B: CQ       |                       |           | B: 32 cases\(^c\), 32.3/7              |
|                     |       |                |            |                       |           | $P = 0.153$                            |
| Nakazato [83]       | T2, T3 | 124           | A: MMC+5-FU+PSK | 73.0/5             | 0.044     |                                        |
|                     |       | 129            | B: MMC+5-FU | 60.0/5                |           |                                        |
| Hattori [13]        | II–III | 1,426        | A: MMC+FT+PSK | 71.6/3              | NS        |                                        |
| JFMC01              |       | 1,357          | B: MMC+FT   | 69.6/3                |           |                                        |
|                     |       | 1,338          | C: MMC+FT+OK-432+PSK | 69.1/3  |           |                                        |
|                     |       | 1,363          | D: MMC+FT+OK-432 | 68.7/3  |           |                                        |
| Ogawa [84]          | I–IV  | 56             | A: MMC+HCFU+PSK | 80.2/5             | 0.811     |                                        |
|                     |       | 55             | B: MMC+HCFU | 81.1/5                |           |                                        |
| JFMC05              | T3, T4 | 215           | A: FT+PSK   | 52.8/5                | NS        |                                        |
|                     |       | 219            | B: FT+OK-432 | 49.3/5                |           |                                        |
|                     |       | 217            | C: FT       | 47.0/5                |           |                                        |
| JFMC11              | T1, T2 | 114           | A: CPA+PSK  | 84.8/5                | NS        |                                        |
|                     |       | 112            | B: surgery alone | 83.3/5             |           |                                        |

**DFS** disease-free survival, **MMC** mitomycin C, **FT** tegafur, **CQ** carboquone, **T** tumor, **5-FU** 5-fluorouracil, **NS** not significant, **OK-432** picibanil, **HCFU** carmofur, **CPA** cyclophosphamide

\(^a\) Excluding mucosal cancer having no lymph node metastasis  
\(^b\) Tumors with serosal invasion  
\(^c\) Tumors with serosal invasion with limited lymph node metastasis
The Chubu block also enrolled curative surgical cases. The subjects were randomized into two groups according to treatment from 2 weeks after surgery: oral tegafur for 3 months followed by PSK for 2 months (one course) for two courses or more (chemotherapy + PSK alternating therapy group), and tegafur for 3 months followed by no treatment for 2 months for two courses or more (intermittent chemotherapy group). Kondo et al. [80] have reported that a subset analysis of subjects having tumors with serosal invasion showed an improved 8-year survival rate in the chemotherapy + PSK alternating therapy group (56.8%) compared with the intermittent chemotherapy group (43.6%) (P = 0.071). Sakamoto et al. [81] also reported that subset analysis of subjects with preserved cellular immunity, as shown by a positive purified protein derivative of tuberculin (PPD) skin test before surgery in this trial, showed an improved survival rate in the chemotherapy + PSK alternating therapy group compared with the intermittent chemotherapy group (P = 0.071). In addition, Kondo et al. [82] have reported that a subset analysis of subjects having tumors with serosal invasion and limited lymph node metastasis showed an improved 7-year survival rate in the chemotherapy (carboquone) + PSK alternating therapy group (43.4%) compared with the intermittent chemotherapy group (32.3%) (P = 0.153) (Tokai Gastrointestinal Oncology Group; TGOG). Based on these findings, the Study Group of Immunochemotherapy with PSK for gastric cancer (SIP) conducted a multicenter RCT on 253 curative surgery cases with T2 or T3 lesions and positive preoperative PPD skin tests. After surgery, MMC was administered intravenously. Four weeks later, one group was given PSK 3 g/day for 4 weeks and then oral 5-FU for 4 weeks (one course) for a total of 10 courses (chemotherapy + PSK alternating therapy group), and the other group was given tegafur alone (intermittent chemotherapy group). As reported by Nakazato et al. [83], the 5-year OS rate in the PSK + chemotherapy alternating therapy and intermittent chemotherapy group was 73.0 and 60.0%, respectively (P = 0.044), and the DFS rate was 70.7 and 59.4%, respectively (P = 0.047), which showed significantly better survival with PSK + chemotherapy alternating therapy (Fig. 5).

---

**Table 5 RCTs of postoperative adjuvant chemotherapy with PSK for resected colorectal cancer**

| References | Stage      | No. of patients | Treatment                      | Percent survival/years | P value | Suggestive data (percent survival/years) |
|------------|------------|-----------------|--------------------------------|------------------------|---------|----------------------------------------|
| Torisu [88] | Stage III, IV | 55              | A: PSK                         | Improvement of DFS and OS | <0.05   |                                        |
|            |            | 56              | B: Placebo                     |                        |         |                                        |
| Takashima [89] | Dukes’ A–C | 53              | A: MMC + FT supp + PSK         | 91.4/6                 | 0.139   | A: 30 cases, 90.2/6                     |
|            |            | 71              | B: MMC + FT supp               | 80.8/6                 |         | B: 39 cases, 70.9/6                     |
|           |            |                 |                                |                        |         | P < 0.05                              |
| Mitomi [90] | Stage III  | 221             | A: MMC+5-FU+PSK                | 78.5/5                 | 0.0325  |                                        |
|            |            | 227             | B: MMC+5-FU                    | 69.7/5                 |         |                                        |
| Ito [91]   | Dukes’ C   | 220             | A: 5-FU+PSK                    | 79.6/7                 | 0.081   | SCD                                    |
|            |            | 221             | B: 5-FU                        | 75.6/7                 |         | A: 83.4/7                              |
|            |            |                 |                                |                        |         | B: 78.5/7                              |
|            |            |                 |                                |                        |         | P = 0.019                              |
| Ohwada [92] | Stage II, III | 137           | A: MMC+UFT+PSK                 | 81.8/5                 | 0.056   | DFS                                    |
|            |            | 68              | B: MMC+UFT                     | 72.1/5                 |         | A: 73.0/5                              |
|            |            |                 |                                |                        |         | B: 58.8/5                              |
|            |            |                 |                                |                        |         | P=0.016                                |

DFS disease-free survival, OS overall survival, MMC mitomycin C, FT tegafur, 5-FU 5-fluorouracil, SCD survival for cancer-related death, UFT tegafur-uracil

* Lymphatic vessel invasion (+)

---

**Fig. 4** Effect of PLCC plus PSK on 15-year OS in patients with advanced gastric cancer after curative resection. Adapted and modified from Maehara et al. [77]
Among the RCTs that have examined the efficacy of PSK in combination with chemotherapy, some could not confirm the efficacy of PSK. The Cooperative Project No. 1 of the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC01) was a large-scale clinical trial that enrolled 7,637 patients in 267 facilities. To clarify the effectiveness of PSK and OK-432, two widely used immunostimulatory compounds, patients were administered MMC intravenously on the day of and 1 day after surgery. From 2 weeks after surgery, the patients received the following treatments for 8 months: oral tegafur only, oral tegafur + PSK 3 g/day, tegafur + intradermal or intramuscular OK-432 0.5–5 KE/day, or tegafur + PSK + OK-432. The 3-year survival rate tended to be higher in groups administered PSK and/or OK-432 [13]. The immune status of the patients was evaluated simultaneously, using the effect of patients’ serum on the PHA blastogenesis reaction of mouse lymphocytes as an indicator. Hattori et al. [13] have reported that the 4-year survival rate was significantly ($P = 0.012$) higher in patients with a high stimulation index, and many patients in the PSK-treated group had a high index.

Ogawa et al. [84] (Kumamoto Gastrointestinal Immunochemotherapy Study Group; KGSG) enrolled 111 patients who underwent curative surgery and treated them 2 weeks after surgery with oral carmofur and PSK 3 g/day (chemotherapy + PSK group), or carmofur alone (chemotherapy group) for 1 year, and observed no difference in 5-year survival rate between the two groups. In the JFMC05 trial, 651 patients with resected T3 or T4 gastric cancer received postoperative tegafur + PSK, tegafur + OK-432, or tegafur alone after surgery. The 5-year survival rate was 52.8% in the tegafur + PSK group, 49.3% in the tegafur + OK-432 group, and 47.0% in the tegafur alone group. Although the rate was apparently higher in the tegafur + PSK group, the difference was not significant (http://jfmc.or.jp/product/prod04/index.html). In the JFMC11 trial, 228 patients with resected T1 or T2 gastric cancer were enrolled. One group received one dose of cyclophosphamide (CPA) and PSK 3 g/day for 1 week before surgery, as well as PSK for 6 months after surgery, and the other group had surgery only. The survival rate did not differ between the two groups (http://jfmc.or.jp/product/prod04/index.html).

The effectiveness of PSK as postoperative adjuvant therapy has been shown in meta-analysis. Oba et al. [85] have identified 47 papers that have compared the survival duration of chemotherapy + PSK with chemotherapy alone in patients who underwent curative surgery for gastric cancer. They excluded duplicated data and selected eight trials of high quality to conduct a meta-analysis. The hazard ratio of 5-year survival was 0.88 [95% confidential interval (CI): 0.79–0.98, $P = 0.018$] (Fig. 6), which verified that chemotherapy + PSK improved survival in patients with curatively resected gastric cancer.

As shown above, the efficacy of PSK as postoperative adjuvant therapy has been verified by a large number of studies. Furthermore, Sugimachi et al. [86] have studied 196 patients with curatively resected, poorly differentiated stage II–IV gastric cancer and treated them with MMC and PSK 3 g/day as the basal postoperative therapy, in combination with two doses of UFT. The recurrence rate was significantly reduced and the 5-year DFS and cause-specific survival rates were significantly ($P < 0.05$) increased in the high-dose UFT (12 mg/kg) group compared with the moderate-dose (8 mg/kg) group. They concluded that combination therapy with high-dose UFT plus PSK improved the postoperative outcome, with no increase in toxicity for poorly differentiated gastric cancer.

After 1990, RCTs were again conducted to examine the effectiveness of postoperative adjuvant chemotherapy compared to surgery alone. At present, TS-1 has become the standard agent for postoperative adjuvant chemotherapy for gastric cancer in Japan [87].

For PSK, the Hokuriku-Kinki Immunochemotherapy Study Group Gastric Cancer (HKIT-GC) group is currently conducting a clinical trial on patients with curatively resected stage II and IIIA gastric cancer. Two groups are being compared: one group is receiving TS-1 for 2 weeks on and 1 week off for 6 months, followed by TS-1 for 2 weeks on and 2 weeks off for 6 months (TS-1 group); and another group is receiving PSK in combination with the above regimen for 1 year (TS-1 + PSK group) (http://clinicaltrials.gov/ct2/home). Another ongoing trial conducted by Tokyo Metropolitan Oncology Group (TMOG) is recruiting curatively resected stage II and III gastric cancer patients and comparing the outcome of treatment with TS-1 alone for 4 weeks on and 2 weeks off (TS-1 group) and PSK in combination with the above regimen (TS-1 + PSK group) for 1 year (http://clinicaltrials.gov/ct2/home).
Colorectal cancer (Tables 5, 6)

The prognosis of surgical treatment for colon and rectal cancers is poor for stage III or higher colon cancer and stage II or higher rectal cancer. For these advanced cancers, postoperative adjuvant therapy is considered necessary. In Japan, many trials have examined the effectiveness of postoperative adjuvant chemotherapy for colorectal cancer using oral fluorinated pyrimidine agents, compared with surgery alone, but few studies have reported the effectiveness of these agents.

The efficacy of PSK on colorectal cancer has been evaluated as postoperative adjuvant therapy. Torisu et al. [88] have conducted a double-blind trial on patients with curatively resected stage III and IV colorectal cancer and compared PSK 1–3 g/day given after surgery until relapse or distant metastasis (PSK group) and placebo (control group). They reported significantly better OS ($P < 0.05$) and DFS ($P < 0.05$) rates in the PSK group.

Thereafter, comparative studies of chemotherapy versus chemotherapy + PSK have been conducted. The Colorectal Cancer Chemotherapy Group in Hokuriku has conducted a multicenter RCT of 124 patients with curatively resected stage III and IV colorectal cancer and compared PSK 1–3 g/day given after surgery until relapse or distant metastasis (PSK group) and placebo (control group). They reported significantly better OS ($P < 0.05$) and DFS ($P < 0.05$) rates in the PSK group.

Test of treatment effect: $P=0.018$

Test of heterogeneity: $x^2(3)=11.7$, $P=0.16$

| Group         | Treatment          | Deaths / Analyzed Case | Hazard ratio (95%CI) |
|---------------|--------------------|------------------------|----------------------|
| SAGG-Kyushu   | MF+PSK             | 54/191                 | 0.620(0.44–0.88)     |
|               | MF                 | 83/199                 |                      |
| SAGG-Chubu    | FT+PSK             | 42/145                 | 0.750(0.50–1.11)     |
|               | FT                 | 58/159                 |                      |
| TGOG          | CQ+PSK             | 27/47                  | 1.050(0.62–1.79)     |
|               | CQ                 | 27/49                  |                      |
| KQSG          | MHC+PSK            | 11/56                  | 1.050(0.44–2.53)     |
|               | MHC                | 9/55                   |                      |
| SIP           | MFU+PSK            | 33/124                 | 0.620(0.40–0.94)     |
|               | MFU                | 52/129                 |                      |
| JMTC-1a       | MT+PSK             | 654/1601               | 0.970(0.87–1.08)     |
|               | MT                 | 627/1509               |                      |
| JMTC-1b       | MT+OK+432+PSK      | 642/1544               | 0.950(0.85–1.06)     |
|               | MT+OK+432         | 672/1549               |                      |
| JMTC-5        | T+PSK              | 101/215                | 0.850(0.65–1.10)     |
|               | T                  | 115/217                |                      |
| JMTC-11       | PSK                | 19/114                 | 0.900(0.48–1.69)     |
|               | Surgery alone      | 20/112                 |                      |
| Total         | PSK Group          | 1583/4037              | 0.880(0.79–0.98)     |
|               | Control Group      | 1663/3972              |                      |

($P < 0.05$) higher in the chemotherapy + PSK group. The Cooperative Study Group of Surgical Adjuvant Immunchemotherapy for Cancer of Colon and Rectum (Kanagawa) has conducted a multicenter RCT on 448 patients who underwent macroscopic curative surgery for stage III and IV colorectal cancer. After treatment with intravenous MMC on the day of and 1 day after surgery, the subjects were randomized 2–3 weeks later to receive oral 5-FU for at least 6 months and PSK for at least 3 years (chemotherapy + PSK group), or 5-FU alone (chemotherapy group). Mitomi et al. [90] have reported that the 5-year DFS ($P = 0.0302$) and survival ($P = 0.0325$) rates were significantly higher in the chemotherapy + PSK group compared to the chemotherapy group (5-year DFS rates: 72.3 vs. 63.2%; 5-year survival rates: 78.5 vs. 69.7%).

The Study Group of Immunochemotherapy with PSK for colon cancer has conducted a multicenter RCT on 441 colon cancer patients with macroscopic Dukes’ C cancer after curative resection. After surgery, continuous intravenous infusion of 5-FU was administered and the patients were randomized at 4 weeks after surgery to receive oral PSK 3 g/day for 4 weeks, followed by oral 5-FU for 4 weeks (one course) for a total of 10 courses (chemotherapy + PSK alternating therapy), or 5-FU alone (intermittent chemotherapy). Ito et al. [91] have reported that the 7-year cancer death-free survival rate was significantly higher in the chemotherapy + PSK alternating therapy arm (83.4%) than in the intermittent chemotherapy arm (78.5%), with a risk reduction of 40.8%.

The Gunma Oncology Study Group has conducted a multicenter RCT on 205 patients with curatively resected...
stage II or III colorectal cancer. Two weeks after intravenous MMC (given on the day of surgery and the following day), one group received oral UFT and PSK 3 g/day for 2 years (chemotherapy \textit{\&} PSK group), and the other group received oral UFT alone (chemotherapy group). Ohwada et al. [92] have reported that the 5-year DFS rate was significantly ($P = 0.016$) higher in the chemotherapy \& PSK group (73.0%) compared with the chemotherapy group (58.8%). Combined therapy with PSK reduced the risk of recurrence by 43.6%. The mean DFS period was significantly ($P = 0.031$) prolonged in the chemotherapy \& PSK group (50.3 months) compared with the chemotherapy group (40.0 months). The 5-year OS rate was higher in the chemotherapy + PSK group (81.8%) than in the chemotherapy group (72.1%), although there was no significant difference ($P = 0.056$). Furthermore, they reported an adverse event rate of 15.1% for both groups, with no grade 3 or 4 events. They concluded that, compared with combined intravenous 5-FU and leucovorin (LV) treatment, for which many grade 3 or higher adverse events have been reported, UFT + PSK therapy was a useful adjuvant therapy that did not require frequent hospital visits and had few adverse reactions.

Sakamoto et al. [93] have performed a meta-analysis of three RCTs that were conducted and published between 1980 and 2004 on curatively resected colorectal cancer patients and compared chemotherapy + PSK with chemotherapy alone. The overall survival risk ratio was 0.71 (95% CI 0.55–0.90, $P = 0.006$) and the DFS risk ratio was 0.72 (95% CI 0.58–0.90, $P = 0.003$), which showed a significant survival benefit of combined therapy with PSK (Fig. 7). Their study confirms the significance of using PSK in postoperative adjuvant therapy for colorectal cancer and opens the possibility of developing improved therapy for colorectal cancer.

Several ongoing studies on PSK have been examining various combination therapy regimens used as postoperative adjuvant therapy. The Hokkaido Gastrointestinal Cancer Study Group, Colorectal Adjuvant Chemotherapy Division (HGCSG-CAD) has been comparing 6 months UFT \& LV therapy (UFT \& LV group), 6-month UFT \& LV with UFT extended for 1 year (UFT \& LV group), and UFT \& PSK therapy was a useful adjuvant therapy that did not require frequent hospital visits and had few adverse reactions.

Sakamoto et al. [93] have performed a meta-analysis of three RCTs that were conducted and published between 1980 and 2004 on curatively resected colorectal cancer patients and compared chemotherapy + PSK with chemotherapy alone. The overall survival risk ratio was 0.71 (95% CI 0.55–0.90, $P = 0.006$) and the DFS risk ratio was 0.72 (95% CI 0.58–0.90, $P = 0.003$), which showed a significant survival benefit of combined therapy with PSK (Fig. 7). Their study confirms the significance of using PSK in postoperative adjuvant therapy for colorectal cancer and opens the possibility of developing improved therapy for colorectal cancer.

Several ongoing studies on PSK have been examining various combination therapy regimens used as postoperative adjuvant therapy. The Hokkaido Gastrointestinal Cancer Study Group, Colorectal Adjuvant Chemotherapy Division (HGCSG-CAD) has been comparing 6 months UFT \& LV therapy (UFT \& LV group), 6-month UFT \& LV with UFT extended for 1 year (UFT \& LV group), and UFT \& PSK therapy was a useful adjuvant therapy that did not require frequent hospital visits and had few adverse reactions.

| Title of the study                                                                 | Organizations/sponsors                                      | Tumor               | Stage | Treatment regimen                                                                 |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------|---------------------|-------|-----------------------------------------------------------------------------------|
| Randomized controlled study of postoperative adjuvant therapy for gastric cancer using TS-1 or TS-1 + PSK | Hokuriku-Kinki Immunochemotherapy Study Group Gastric Cancer (HKIT-GC) | Gastric cancer      | II, IIIA | TS-1 (1 year) / TS-1 + PSK (1 year)                                               |
| Study of TS-1 or TS-1 + PSK for gastric cancer patients                            | Tokyo Metropolitan Oncology Group (TMOG)                    | Gastric cancer      | II, III | TS-1 (1 year) / TS-1 + PSK (1 year)                                               |
| Randomized phase III adjuvant study for stage III colorectal cancer                | Hokkaido Gastrointestinal Cancer Study Group, Colorectal Adjuvant Chemotherapy Division (HGCSG-CAD) | Colorectal cancer   | III    | UFT + LV (5 courses) / UFT + LV (5 courses) / UFT (1 year) / UFT + LV + PSK (5 courses) / UFT + PSK (1 year) |
| Uracil and tegafur/leucovorin (UFT/LV) versus UFT/LV + PSK for stage IIIa/IIIb colorectal cancer | Iwate Clinical Oncology Group, Colorectal Cancer (ICOG-CC)  | Colorectal cancer   | IIIa, IIIb | UFT + LV / UFT + LV + PSK                                                         |
| Phase III trial comparing UFT + PSK to UFT + LV in stage IIIB, III colorectal cancer | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSOG-CCTG) | Colorectal cancer   | IIB, III | UFT + PSK (1 year) / UFT + LV (6 months)                                           |
| Phase III trial comparing surgery alone to UFT + PSK in stage II rectal cancer     | Japanese Foundation for Multidisciplinary Treatment of Cancer | Rectal cancer       | II     | Surgery alone / UFT + PSK (1 year)                                                 |

TS-1 tegafur–gimeracil–oteracil potassium, UFT tegafur-uracil, LV leucovorin
group), and PSK added on to the latter regimen (UFT + LV + PSK/UFT + PSK group) in patients with curatively resected stage III colorectal cancer (http://clinicaltrials.gov/ct2/home). The Iwate Clinical Oncology Group, Colorectal Cancer (ICOG-CC) trial has been comparing UFT + LV with UFT + LV + PSK in patients with curatively resected stage IIIa and IIIb colorectal cancer (http://clinicaltrials.gov/ct2/home). The Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO-CCTG) has been comparing UFT + LV with UFT + LV + PSK in patients with curatively resected stage IIB and III colorectal cancer (http://clinicaltrials.gov/ct2/home). In the JFMC38-0901 trial, the effect of 12 months UFT + PSK therapy compared with surgery alone is being evaluated in patients with curatively resected stage II rectal cancer (http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=list&language=J).

Lung cancer (Table 7)

Konno et al. [94] have compared the combination of intravenous vincristine (VCR), cyclophosphamide (CPA), and MMC once weekly for 8 weeks with or without 8–10 Gy radiotherapy (chemotherapy/radiotherapy group) with the combination of PSK 3 g/day added to the above regimen (chemotherapy/radiotherapy + PSK group) in 97 patients with small-cell lung carcinoma. Although the response rates did not differ between the two groups, the median response duration was significantly \( P = 0.042 \) longer in the chemotherapy/radiotherapy + PSK group (25 weeks) than in the chemotherapy/radiotherapy group (13 weeks). Evidence for combined use of PSK and currently used chemotherapy regimen for extensive-stage small-cell lung cancer is anticipated; therefore, the Research Network for Chemotherapy of Lung Cancer (RNCLC) has been conducting a phase II trial to examine the effect of cisplatin + irinotecan + PSK compared with historical controls (http://clinicaltrials.gov/ct2/home).

To examine the usefulness of PSK as postoperative adjuvant therapy for lung cancer, Ikeda et al. [95] have studied 113 patients with non-small cell lung cancer randomized after surgery into three groups: chemotherapy with VCR, MMC, methotrexate, CPA or 5-FU combined with PSK 3 g/day (chemotherapy + PSK group); chemotherapy combined with OK-432 (chemotherapy + OK-432 group); and chemotherapy alone (chemotherapy group). The three-group comparison detected a significant difference \( P < 0.05 \) in the 4-year survival, and the two-group comparisons found a significant difference \( P < 0.05 \) between the chemotherapy + PSK and chemotherapy groups.

Hayakawa et al. [96] have investigated PSK therapy in 188 patients with non-small cell lung cancer, mainly stages I–III squamous cell cancer, who had achieved complete or partial response after radiotherapy. The patients were randomized to receive adjuvant treatment with PSK intermittent administration of 3 g/day for 2 weeks followed by 2 weeks off, or no adjuvant treatment. The 5-year survival rate was significantly \( P < 0.001 \) higher in the group given PSK. As demonstrated in these studies, PSK is effective also for non-small cell lung cancer.

| References | Tumor characteristics | No. of patients | Treatment | Response rate (%) or percentage survival/year | \( P \) value | Suggestive data | Duration of tumor response |
|------------|------------------------|-----------------|-----------|-----------------------------------------------|--------------|----------------|--------------------------|
| Konno [94] | Small-cell lung cancer | 48/49           | A: VCR+CPA+MMC (radiation)+PSK | 45/46 | NS A: 25 weeks B: 13 weeks | \( P = 0.042 \) | |
| Ikeda [95] | Non-small cell lung cancer stage I–IV | 27/39/47 | A: VCR+MMC+MTX (CPA, 5-FU)+PSK | 55.9/36.7/34.7 | 3 groups A versus C | \( P = 0.004 \) |
| Hayakawa [96] | Non-small cell lung cancer Stage I–III | 77/111 | A: Radiation+PSK | 30/5 | \( <0.001 \) | |

VCR vincristine, CPA cyclophosphamide, MMC mitomycin C, NS not significant, MTX methotrexate, 5-FU 5-fluorouracil, OK-432 picibanil

\( \copyright \) Springer
Other clinical uses (Tables 8, 9)

A number of reports on the effects of PSK on cancers not included in the approved indications have been published. In one report, nasopharyngeal carcinoma patients who had undergone radiotherapy or radiotherapy + chemotherapy were given PSK or no further treatment. The 5-year survival rate was significantly ($P = 0.043$) improved in the PSK-treated group compared to the non-PSK-treated group [97]. Patients with primary or relapsed superficial bladder cancer were randomized after surgery to receive PSK, chemotherapy with carboquone, or chemotherapy + PSK, and were compared with surgery alone. The 3-year DFS rate was significantly better in the PSK-treated group compared with surgery alone ($P = 0.008$) or the chemotherapy-treated group ($P = 0.006$) [98]. In esophageal cancer patients treated postoperatively with radiotherapy, or radiotherapy combined with PSK or radiotherapy + chemotherapy (bleomycin, or pepleomycin + tegafur), or radiotherapy + chemotherapy combined with PSK, the 5-year survival tended to be prolonged in the radiotherapy + chemotherapy + PSK group compared with the radiotherapy + chemotherapy group, although the difference was not significant ($P = 0.1034$) [99]. Breast cancer patients were treated with postoperative chemotherapy (5-FU + CPA + MMC + prednisolone) with or without PSK. The 10-year OS rate tended to be higher ($P = 0.0706$) in the PSK-treated group compared with the group given chemotherapy alone [100]. Although BRMs such as PSK have a direct effect on tumors, their major action is to enhance and modulate the immune response, which can account for a reasonable degree of effectiveness against various tumor types.

Few adverse reactions from the use of PSK have been reported, and most of them are gastrointestinal symptoms with no report of serious toxicity such as bone marrow suppression, or liver or renal function impairment [76, 88, 101]. PSK is relatively non-toxic and it has been reported to attenuate the adverse reactions or immunosuppression induced by chemotherapy or radiotherapy [102, 103]. Furthermore, Yoshimura et al. [104] have examined the quality of life (QOL) of 20 patients with unresectable stage III and IV lung adenocarcinoma treated with chemotherapy (cisplatin + vindesine) + PSK or chemotherapy alone, and found that good QOL was maintained in the patients treated with chemotherapy + PSK. Motai et al. [105] have investigated the frequency of prescription of analgesics for cancer pain in head and neck cancer, by comparing those treated and not treated with PSK. They reported significantly ($P < 0.05$) reduced frequency of analgesic use in

| Table 8 RCTs of chemotherapy and/or radiotherapy with PSK for various cancers |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| References | Tumor characteristics | No. of patients | Treatment | Results | $P$ value |
| Go [97] | Nasopharyngeal carcinoma | 17 | A: RT(±CT$^a$) + PSK | 28% | 0.043 |
| | | 17 | B: RT(±CT) | 15% | |
| Matsumoto [98] | Superficial bladder tumor | 65 | A: Resection+PSK | 56.3% | 0.026 |
| | | 67 | B: Resection only | 32.6% | A versus B |
| | | 65 | C: Resection+CQ+PSK | 43.1% | 0.008 |
| | | 66 | D: Resection+CQ | 35.6% | A versus D |
| Ogoshi [99] | Esophageal cancer | 38 | A: Resection+RT+PSK | 42.3% | C versus D |
| | stage I-IV | 31 | B: Resection+RT | 40.0% | 0.1930 |
| | | 56 | C: Resection+RT+CQ$^b$+PSK | 37.2% | |
| | | 49 | D: Resection+RT+CQ | 29.1% | |
| | | | | | |
| | | | | | |
| Iino [100] | Breast cancer | 74 | A: Resection+FEMP$^c$+PSK | 81.8% | 0.1686 |
| | | 76 | B: Resection+FEMP+Levamisole | 76.9% | A versus C |
| | | 77 | C: Resection+FEMP | 64.6% | 0.0706 |

RT radiotherapy, CT chemotherapy, DFS disease-free survival, pT pathologic tumor, G grade, CQ carboquone

$^a$ Cisplatin or 5-FU or methotrexate or vincristine

$^b$ Bleomycin or pepleomycin+tegafur

$^c$ 5-FU+CPA+MMC+prednisolone
patients treated with PSK, which suggested that PSK had some effect on cancer pain relief. Apart from its anticancer effects, PSK is a useful agent in cancer treatment as shown by the above studies.

**Concluding remarks and future perspectives**

Recent developments in the investigations of the mechanisms of action of PSK and its main clinical effects have been reviewed. Regarding the action of PSK against immunosuppression, PSK has been reported to restore or attenuate immunosuppression due to various factors. With regard to the actions on immune cells, the induction of DC maturation, the correction of Th1/Th2 imbalance, etc. have been reported. Furthermore, the involvement of PSK in intracellular signal transduction pathways also begins to unfold. With regard to the direct action on tumors, considerable knowledge about apoptosis induction by PSK has been accumulating, and the anti-metastatic effect and chemotherapy potentiating effect due to direct action on tumors have been reported. Future studies of the actions of PSK on immune cells and tumor cells at the molecular level under various conditions, and identification of the target molecules of PSK, are necessary to clearly define the whole mechanisms of action of PSK. Furthermore, it is essential to investigate the actions of PSK along with recent advances in molecular biology and tumor immunology. Although many research results on the mechanisms of action of PSK have been reported, it is undeniable that the main mechanism of action is unclear. It seems that PSK is an immunomodulator rather than a purely immunopotentiator \[106\]. PSK probably does not exert the same actions in all patients. The effects of PSK under different local (tumor site) or systemic immune conditions and tumor cell properties, and the mechanism of action of PSK in each circumstance should be studied.

The beneficial effect of PSK as postoperative adjuvant therapy for gastric and colorectal cancer has been shown in multiple RCTs. In addition, the effects of PSK in gastric and colorectal cancer have been verified in multiple meta-analyses. Prolongation of the remission period has also been found in small-cell lung cancer. The combined effect or comparison of combined formulation and biochemical modulation of fluoropyrimidine anticancer agents is being examined by RCTs, and the results will be available in the near future. Besides gastric, colorectal and small-cell lung cancer, PSK also exhibits reasonable effects on other cancers. These results are expected, because, unlike chemotherapy agents, PSK exerts anticancer effects through acting on host immunity. Also, PSK causes few adverse reactions and has been reported to reduce those associated with chemotherapy, improve QOL, and mitigate cancer pain. The next step of PSK research is to define which type of patient and disease conditions will allow PSK to exert its optimal effect, irrespective of cancer type. In this regard, there is an urgent need to elucidate the mechanisms of action of PSK at the molecular level so as to identify the biomarkers. Achievement of these goals will benefit patients from the personalized medicine point of view.

Several reports have already suggested that the patient’s immune function, as indicated by blood IAP level, peripheral granulocyte/lymphocyte ratio, and DC infiltration of

### Table 9 Other effects of PSK in cancer therapy

| References | Evaluation | Tumor characteristics | No. of patients | Treatment | Results |
|------------|------------|-----------------------|----------------|-----------|---------|
| Kohara \[102\] | Toxicity of chemotherapy | Solid tumors | 20/49 | A: 5-FU (dry syrup) + PSK | Frequency of chemotherapy toxicity |
| Sadahiro \[103\] | Immune cells | Rectal cancer | 15/15 | A: RT+S-1+PSK (preoperative) | Increases of the proportion of NK cells in the peripheral blood \(P = 0.003\) and cytotoxic T-cell counts in the peri-tumoral and normal mucosa \(P = 0.005, 0.003\) |
| Yoshimura \[104\] | QOL | Stage III, IV adenocarcinoma of the lung, inoperable | 10/10 | A: CDDP+VDS+PSK | Good score of QOL \(A > B\) |
| Motai \[105\] | Cancerous pain | Nasopharyngeal carcinoma | 31/31 | A: PSK | Frequency of analgesic use |

\(5-FU\) 5-fluorouracil, \(RT\) radiation therapy, \(S-1\) tegafur–gimeracil–oteracil potassium, \(CDDP\) cisplatin, \(VDS\) vindesine, \(QOL\) quality of life
Table 10 Potential biomarkers of PSK

| Subjects                          | Potential biomarker                                             | References |
|----------------------------------|-----------------------------------------------------------------|------------|
| Human colon cancer cell line (in | Expression of ECA39 protein in tumor cells                     | Yoshikawa  |
| vitro)                           |                                                                  | [111]      |
| Colon cancer patients            | Diffuse nuclear accumulation of β-catenin activation in primary | Yamashita  |
|                                  | tumor                                                            | [112]      |
| Colon cancer patients            | Preoperative peripheral blood CEA level: ≥3.0 ng/ml             | Takahashi  |
|                                  | Preoperative PPD skin reaction level: <19.0 nm                   | [113]      |
| Colorectal cancer patients       | Increase of NK cell population in peripheral blood after PSK    | Ohwada     |
|                                  | administration                                                  | [114]      |
| Colorectal cancer patients       | Ratio of CD4+ IL-10+ T-cell percentage in peripheral blood before | Yoshino    |
|                                  | and after PSK treatment: <0.8                                    | [46]       |
| Gastric or colorectal cancer     | In vitro activation level of peripheral blood lymphocytes by PSK | Yoshinaga  |
| patients                         |                                                                  | [116]      |

CEA carcinoembryonic antigen, PPD purified protein derivative of tuberculin, NK natural killer

Fig. 8 PSK-stimulated activation of blood lymphocytes in healthy volunteers and cancer patients (a). Effects of adjuvant immunochemotherapy with PSK on 10-year OS in gastric cancer (b) and colorectal cancer (c) patients with low or high PSK-induced lymphocyte activation level. The increase in DNA synthesis of lymphocytes was defined as ratio of the level of PSK-treated lymphocytes versus PSK-non-treated lymphocytes. Asterisk adjusted by gender, age, Dukes’ stage, tumor size, lymphatic vessel invasion, and venous invasion. Adapted from Sugimachi et al. [115] and Yoshinaga et al. [116]
tumor tissue, as well as HLA type, is a potential biomarker of response to PSK therapy [107–110]. The recent advances in biomarker research are summarized in Table 10. Yoshikawa et al. [111] have examined the action of PSK on human colorectal cancer cell line, using protein microarray with antibodies against 500 human proteins and found that expression of ECA39 protein was reduced. ECA39 expression in resected tumors is associated with poor DFS and OS; therefore, these findings suggest that ECA expression is a marker of response to PSK therapy. Yamashita et al. [112] have examined nuclear translocation of β-catenin in cancer tissues of colorectal cancer patients and reported that OS was improved with PSK immunotherapy in patients showing diffuse β-catenin nuclear accumulation in tumor tissues. Takahashi et al. [113] have reported that, in colon cancer patients with preoperative peripheral blood carcinoembryonic antigen level: ≥3.0 ng/ml or PPD skin reaction level: <19.0 mm, 7-year DFS and OS were significantly better with postoperative adjuvant immunochemotherapy using PSK than in patients treated with chemotherapy alone. Ohwada et al. [114] have reported that colorectal cancer patients with an increase in NK cell population at 3 months after surgery had more favorable DFS when treated with PSK immunotherapy than chemotherapy alone. Yoshino et al. [46] have found that relapse (3 years) did not occur in colorectal cancer patients with peripheral blood CD4+ IL-10+ T-cell ratios (post-/pre-PSK treatment): <0.8 when PSK was administered 1 week before surgery, and reported that these patients might be candidate PSK responders. We have examined the outcome in gastric and colorectal cancer patients using the PSK-induced peripheral blood lymphocyte blastogenesis reaction as an indicator for response to PSK therapy and gained an impression that patients with high reactivity had better survival outcome (Fig. 8) [115, 116]. We have also investigated the in vitro effect of PSK on PBMC gene expression in healthy individuals using DNA microarray analysis and observed changes in expression of six genes in four of five individuals. Using real-time RT-PCR, we found increased expression of IL-18BP, CCL2, IL-8, and vesicle amine transport 1 homolog and reduced expression of chondroitin sulfate proteoglycan in all five individuals [117]. The relationship between expression of these genes and relapse suppression needs to be examined further. We speculate that more than one biomarker might indicate response to PSK therapy. Identification of these biomarkers one by one will pave the way for the future use of PSK in cancer treatment.

**Conflict of interest** Y.M. has received honoraria and research funding from Daiichi Sankyo Co. Ltd. and Kureha Corp. H.B. has received research funding from Daiichi Sankyo Co. Ltd. All other authors declare no conflicts of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**References**

1. van der Bruggen P, Traversari C, Chomez P, Lorquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–4.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–80.
5. Yoshimura K, Oino K, Edil BH, Schulick RD, Oka M. Immuno-and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today, 2010;40:404–10.
6. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Grammont A, et al. Poised safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:1948–55.
7. Donaldson SS, Lenon RA. Alterations of nutritional status: impact of chemotherapy and radiation therapy. Cancer. 1979;43:2036–52.
8. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H. Prognostic value of preoperative immunosuppressive effects of CD4+ CD107+ T-cell in patients with gastric cancer: findings from three independent clinical trials. Cancer. 1996;77:2206–12.
9. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.
10. Tsukagoshi S, Hashimoto Y, Fujiyama G, Kobayashi H, Nomoto K, Orita K, Krestin (PSK). Cancer Treat Rev. 1984;10:31–55.
11. Fuji M, Krestin (PSK). Biotherapy. 1996;10:315–7 (in Japanese with English abstract).
12. Matsunaga K, Morita I, Iijima H, Endo H, Oguchi Y, Yoshimura M, et al. Therapeutic application of the PSK-induced peripheral blood mononuclear cell response. Cancer. 1996;77:2206–12.
13. Ohwada T, Sakamoto J, Nakazato H, Tanabe T, Kikuchi K, Abe O, et al. Postoperative adjuvant immunotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg. 1990;20:127–36.
14. Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, Abe K, et al. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer. 1997;70:362–72.
15. Matsunaga K, Hosokawa A, Oohara M, Sugita N, Harada M, Nomoto K. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-β. Immunopharmacology. 1998;40:219–30.
16. Inokuchi K, Kumamiro R. Chemotherapy for gastric cancer. Surg Today. 1980;42:40–6 (in Japanese).
17. Yamanaka M, Takahata K, Oka H, Yoshino F, Sugita N, Yoshikumi C. Studies on the mechanisms of antitumor activities of
PSK (Krestin): effects on prostaglandin metabolism of tumor cells. In: Ishigami J, editor. Recent advances in chemotherapy. Proceedings of the 14th ICC. Tokyo: University of Tokyo Press; 1985. p. 896–7.

18. Kobayashi Y, Kariya K, Saigennji K, Nakamura K. Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor Quel with SOD mimicking activity. Cancer Biother. 1994;9:55–62.

19. Yamaguchi Y, Minami K, Ohshita A, Kabawuchi Y, Noma K, Toge T. Enhancing effect of PS-K on IL-2-induced lymphocyte activation: possible involvement of antagonistic action against TGF-beta. Anticancer Res. 2004;24:639–48.

20. Shibata M, Abe H, Kanou H, Azahta T, Nazu T, Ohara M, et al. In vitro and in vivo immune-modulating effects of polysaccharide K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.

21. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa et al. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes by autologous tumor cells. Cancer Immunol Immunother. 1990;4:123–8 (in Japanese with English abstract).

22. Toge T. Enhancing effect of PS-K on IL-2-induced lymphocyte activation: possible involvement of antagonistic action against TGF-beta. Anticancer Res. 2004;24:639–48.

23. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa M, Sano H, et al. Restoration of antibody-forming capacities by PS-K in tumor-bearing mice. J Kyoto Pref Univ Med. 1987:96:927–38.

24. Hirose K, Zachariae C, Oppenheim J, Kouji M. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res. 1990:94:475–83.

25. Ooshiro M, Sugishita Y, Tanaka H, Koide K, Nagashima M, et al. Effect of PSK on either immunocytes or tumor cells. Biotherapy. 1996;10:18–25 (in Japanese with English abstract).

26. Kato H, Kin R, Yamamura Y, Tanigawa M, Sano H, Sugino S, et al. In vitro induction of LAK cells with PSK. Biotherapy. 1990;4:123–8 (in Japanese with English abstract).

27. Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Sugai H, Akaike et al. In vitro and in vivo immune-modulating effects of polysaccharide K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.

28. Nio Y, Shiraishi T, Azahta T, Nezu T, Ohara M, et al. In vitro and in vivo immune-modulating effects of polysaccharide K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.

29. Nio Y, Shiraishi T, Azahta T, Nezu T, Ohara M, et al. In vitro and in vivo immune-modulating effects of polysaccharide K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.

30. Kato H, Kin R, Yamamura Y, Tanigawa M, Sano H, Sugino S, et al. Tumor inhibitory effect of polymorphonuclear leukocytes (PMN) induced by PSK in the peritoneal cavity of tumor-bearing mice. J Kyuto Pref Univ Med. 1987:96:927–38.

31. Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Sugai H, Akaike et al. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes by autologous tumor cells. Cancer Immunol Immunother. 1991;35:341–9.

32. Nio Y, Shiraishi T, Azahta T, Nezu T, Ohara M, et al. In vitro and in vivo immune-modulating effects of polysaccharide K (PSK) in patients with colorectal cancer. Proc AACR. 2002;43:448.
50. Liu A, Klein G, Bandobashi K, Klein E, Nagy N. SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK. Immunol Lett. 2002;82:81–8.

51. Liu A, Arbiser JL, Holmgren A, Klein G, Klein E. PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood. 2005;105:1606–13.

52. Liu A, Claesson HE, Mahshid Y, Klein G, Klein E. Leukotrien B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. Blood. 2008;111:2693–703.

53. Klein E, Liu A, Claesson HE. Activation of innate immunity by the leukotriene B4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunol Lett. 2008;116:174–7.

54. Akagi J, Baba H. PSK may suppress CD57+ T cells to improve survival of advanced gastric cancer patients. Int J Clin Oncol. 2010;15:145–52.

55. Asai Y, Takaori K, Yamamoto T, Ogawa T. Protein-bound polysaccharide isolated from basidiomycetes inhibits endotoxin-induced activation by blocking lipopolysaccharide-binding protein and CD14 functions. FEMS Immunol Med Microbiol. 2005;43:91–8.

56. Miki C, Tanaka K, Inoue Y, Araki T, Ohi M, Mohri Y, et al. Perioperative host–tumor inflammatory interactions: a potential trigger for disease recurrence following a curative resection for colorectal cancer. Surg Today. 2008;38:579–84.

57. Tsutsuki N, Kohno S, Sonoda H, Guntani A, Rikimaru T, Taguchi K, et al. Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncol Lett. 2011;2:791–6.

58. Yanagawa T, Oguro M, Takagi T, Takenaga K. Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test. Jpn J Cancer Chemother. 1984;11:2155–62 (in Japanese with English abstract).

59. Yefenof E, Gafanovitch I, Oron E, Bar M, Klein E. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother. 1995;41:389–96.

60. Araya S, Nio Y, Hayashi H, Masai Y, Tsubono M, Ishigami S, et al. Various plant-derived polysaccharides augment the activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test. Jpn J Cancer Chemother. 1989;16:799–806 (in Japanese with English abstract).

61. Hattori ST, Komatsu N, Shichijo S, Itoh K. Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomed Pharmacother. 2004;58:226–30.

62. Jiménez-Medina E, Bertruguilla E, Romero I, Bar M, Klein E. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother. 1995;41:389–96.

63. Araya S, Nio Y, Hayashi H, Masai Y, Tsubono M, Ishigami S, et al. Various plant-derived polysaccharides augment the expression of HLA on Colo 205 human colonic cancer line. Jpn J Soc Cancer Ther. 1994;29:1655–73 (in Japanese with English abstract).

64. Hattori ST, Komatsu N, Shichijo S, Itoh K. Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomed Pharmacother. 2004;58:226–30.

65. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.

66. Hayashida T, Konagi A, Hasegawa H, Ishii Y, Endo T, Oka-bayashi K, et al. Inhibitory ability of a protein-bound polysaccharide, PSK, on transforming growth factor beta pathway and EMT. In: Proceedings of the JCA. 2009; p. 47.

67. Kumar S, Saitoh K, Kumar P. Angiogenesis: key principles–science–technology–medicine. In: Steiner R, Weisz PB, Langer R, editors. Antiangiogenesis strategies in cancer therapy with special reference to Krestin. Basel: Birkhauser Verlag; 1992. p. 463–70.

68. Wada T, Wakamatsu Y, Bannai K, Mato M, Oguchi Y, Matsu-naga K, et al. Suppression mechanism of angiogenesis by PSK. Ann Cancer Res Ther. 2002;10:93–106.

69. Konno H, Yamamoto M, Ohta M. Recent concepts of antiangiogenic therapy. Surg Today. 2010;40:494–500.

70. Yoshikawa R, Yanagi H, Hashimoto-Tamaoki T, Morinaga T, Nakano Y, Noda M, et al. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells. Oncology Rep. 2004;12:1287–93.

71. Zhang H, Morisaki T, Nakahara C, Matsu-naga S, Sato N, Na-gumo F, et al. PSK-mediated NF-κB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene. 2003;22:2088–96.

72. Kinoshita J, Fushida S, Harada S, Makino I, Nakamura K, Oya-ma K, et al. PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression. Int J Oncol. 2010;36:593–600.

73. Sakurai Y, Azuma I, Ishihara K, Ogura T, Saito T, Simoyama M, et al. Method for evaluation of efficacy of immunopotentiating agent on malignant tumor. Pharm Regul Sci. 1980;11:764–8 (in Japanese).

74. Nakao I, Yokoyama T, Urushizaki I, Waku A, Furue H, Koyama Y, et al. Clinical outcome of PSK for advanced gastric cancer—results of randomized control trial. Oncologia. 1985;14:163–9 (in Japanese).

75. Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: a comprehensive review. Gastric Cancer. 2001;4:175–84.

76. Kondo M, Torisu M, Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Torisu M, Yoshida T, editors. Basic mechanisms and clinical treatment of tumor metastasis. Orlando: Academic Press; 1985. p. 623–36.

77. Maehara Y, Moriguchi S, Sakaguchi Y, Emi Y, Kohnoe S, Tsujitani S, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990;45:160–72.

78. Nakajima T, Inokuchi K, Hattori K, Inoue K, Taguchi T, Kon-dou T, et al. Multi-institutional cooperative study of adjuvant immunochemo-therapy for gastric cancer—five-year survival rate. Jpn J Cancer Chemother. 1989;16:799–806 (in Japanese with English abstract).

79. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N. Postoperative adjuvant immunomochemothery with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg. 1988;18:681–6.

80. Kondo T, Ichihashi H, Nakazato H, Ogawa N. Results of adjuvant immunochemothery on 8-year survival using KRESTIN® and Futraful® for gastric cancer patients who underwent radical gastrectomy—a randomized controlled trial by cooperative study group. Biotherapy. 1989;3:655–64 (in Japanese with English abstract).

81. Sakamoto J, Nakazato H, Koike A, Saji S. Pitfalls in the clinical evaluation of surgical adjuvant immunomochemothery for the multidisciplinary treatment of gastrointestinal cancers. Biotherapy. 1993;7:1759–64 (in Japanese with English abstract).

82. Kondo T, Sakamoto J, Nakazato H. Alternating immuno-mochemothery of advanced gastric carcinoma: a randomized
comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy. 1991;3:287–95.

83. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994;343:1122–6.

84. Ogawa M, Kako H, Kitano K, Matsukane H, Nagao K, Misumi A, et al. Cooperative study of adjuvant immunochemotherapy using HUFU (Mifurol®) for gastric cancer patients who underwent curative resection. Rinsho To Kenkyu. 1994;71:201–6 (in Japanese).

85. Oba K, Teramukai S, Kobayashi M, Matsu T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56:905–11.

86. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol. 1997;40:233–8.

87. Fuji M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.

88. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Nakamoto J. Efficacy of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997;21:71–7.

89. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.

90. Takashima S, Kinami Y, Miyazaki I. Clinical effect of postoperative adjuvant immunotherapy with FT-207 suppository and PSK for colo-rectal cancer patients. Jpn J Cancer Chemother. 1988;15:2229–36 (in Japanese with English abstract).

91. Mitomi T, Tsuchiya S, Iijima N, Aso K, Nishiyama K, Takashima S, Kinami Y, Miyazaki I. Clinical effect of postoperative adjuvant immunotherapy with 5-fluorouracil dry syrup and combination chemotherapy with 5-fluorouracil dry syrup and PSK for cancer patients. Jpn J Cancer Chemother. 1979;6:379–85 (in Japanese with English abstract).

92. Nomoto K, Matsuo K. Role of immunopotentiators in immunotherapy for colorectal cancer—5 years follow-up after surgery (a final report). J Jpn Soc Cancer Ther. 1993;28:71–83 (in Japanese with English abstract).

93. Ito K, Nakazato H, Koike A, Takagi H, Saji S, Baba S, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis. 2004;19:157–64.

94. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, et al. Efficacy of adjuvant immunochemotherapy with oral polysaccharide K(PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31:261–8.

95. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Ikeda T, Sakai T, Suito T, Kosaki G. Evaluation of postoperative immunochemotherapy using HUFU (Mifurol®) for gastric cancer patients who underwent curative resection. Rinsho To Kenkyu. 1994;71:201–6 (in Japanese).

96. Konno K, Motomiya K, Oizumi K, Sato M, Yamamoto F, Tamiya K, et al. Effects of protein-bound polysaccharide preparation of dendritic cells for patients with advanced gastric cancer. Cancer Immunol Immunother. 1990;31:261–8.

97. Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res. 1989;17:141–9.

98. Matsumoto K, Nakagami Y, Kishimoto T. The prevention of recurrence of superficial bladder tumours with immunochemotherapy. In: deKernion JB, editor. International society of urology reports. Immunotherapy of urological tumours. Edinburgh: Churchill Livingstone; 1990. p. 49–55.

99. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Immuonotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Am J Clin Oncol. 1995;18:216–22.

100. Iino Y, Yokoe T, Maemura M, Horiguchi J, Takei H, Ohwada S, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995;15:2907–11.

101. Pharmaceutical Affairs Bureau, Ministry of Health and Welfare (Japan). Ethical drug side effect information no. 48. 1982; p. 220–3 (in Japanese).

102. Kohara K, Arima S, Tamesue N, Shimura H. Toxicities in single chemotherapy with 5-fluorouracil dry syrup and combination chemotherapy with 5-fluorouracil dry syrup and PSK for cancer patients. Jpn J Cancer Chemother. 1979;6:379–85 (in Japanese with English abstract).

103. Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Kimjo A, Murayama C, Nakayama Y, Akiba T, et al. Effects of preoperative immunomodulation for colorectal cancer patients. Jpn J Cancer Chemother. 1988;15:2229–36 (in Japanese with English abstract).

104. Matoh H. PSK effectiveness for cancer pain relief: clinical study covering the last 11 years. Biotherapy. 1992;6:950–6 (in Japanese with English abstract).

105. Nomoto K, Matsuo K. Role of immunopotentiators in immunotherapy. Jpn J Cancer Chemother. 1978;5:1135–41 (in Japanese with English abstract).

106. Takemura T, Sakaguchi Y, Kakimoto Y, Ito K, Nomoto K, et al. Immunomodulation by polysaccharide K304 in colorectal cancer patients. Jpn J Cancer Chemother. 1979;6:379–85 (in Japanese with English abstract).

107. Sakamoto J, Morita S, Oba K, Matsu T, Kobayashi M, Nakazato H, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resected colorectal cancer: a meta-analysis of centrally randomized controlled trials. Cancer Immunol Immunother. 2006;55:404–11.

108. Konno K, Motomiya M, Oizumi K, Sato M, Yamamoto F, Tamiya K, et al. Effects of protein-bound polysaccharide preparation (PSK) in small cell carcinoma of the lung. JJLC. 1988;28:19–28 (in Japanese with English abstract).

109. Ikeda T, Sakai T, Suito T, Kosaki G. Evaluation of postoperative immunotherapy for lung cancer patients. Jpn J Cancer Chemother. 1986;13:1044–9 (in Japanese with English abstract).

110. Ogoshi K, Tajima T, Mitomi T, Mukuchu, Tsuji K. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother. 1997;45:53–9.

111. Yoshimura A, Asakawa M, Nakai H, Sakai H, Nishiwaki Y, Furuse K, et al. Combined effects of PSK with chemotherapy in the treatment of adenocarcinoma of the lung. Assessment of quality of life (QOL). Biotherapy 1992;6:256–7 (in Japanese with English abstract).

112. Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep. 2000;7:1157–61.

113. Tsujitani S, Kakeji Y, Orita H, Watanabe A, Kohnoe S, Baba H, et al. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res. 1992;12:645–8.

114. Ogoshi K, Tajima T, Motomi T, Makuchu, Tsuji K. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother. 1997;45:53–9.

115. Yoshikawa R, Yanagi H, Shen CH, Fujiwara Y, Noda M, Nagaya T, et al. ECA39 is a novel distant metastasis-related biomarker for colorectal cancer. Clin Cancer Res. 2009;15:699–707.

116. Yamashita K, Ogolovok AV, Nakazato H, Ito K, Ohashi Y, Kitakata H, et al. Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic β-catenin activation. Dis Colon Rectum. 2007;50:1169–81.

117. Takahashi Y, Mai M, Nakazato H. Preoperative CEA and PPD values as prognostic factors for immunotherapy using PSK and 5-FU. Anticancer Res. 2005;25:1377–84.

118. Ohwada S, Ogawa T, Makita F, Tanahashi Y, Ohyo T, Tomizawa N, et al. Beneficial effects of protein-bound polysaccharide

2 Springer
K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep. 2006;15:861–8.

115. Sugimachi K, Maehara Y, Kusumoto T, Okamura T, Korenaga D, Kohnoe S, et al. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer. Anticancer Res. 1995;15:2175–80.

116. Yoshinaga K, Saeki H, Endo K, Morita M, Emi Y, Kakeji Y, et al. Biomarker research of Krestin (PSK) therapy in gastric and colorectal cancer patients. J Jpn Soc Clin Oncol. 2008;43:900.

117. Sugiyama M, Yoshino I, Kakeji Y, Maehara Y. Gene expression profile in human peripheral blood mononuclear cells upon PSK stimulation. In: Proceedings of the JCA. 2008; p. 452.